152 related articles for article (PubMed ID: 11895902)
41. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
Bai M; Agnantis NJ; Skyrlas A; Tsanou E; Kamina S; Galani V; Kanavaros P
Mod Pathol; 2003 May; 16(5):471-80. PubMed ID: 12748254
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
Ohsawa M; Ikura Y; Fukushima H; Shirai N; Sugama Y; Suekane T; Hirayama M; Hino M; Ueda M
Oncology; 2005; 68(4-6):422-31. PubMed ID: 16020972
[TBL] [Abstract][Full Text] [Related]
43. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas.
Paydas S; Ergin M; Erdogan S; Seydaoglu G
Leuk Res; 2008 Sep; 32(9):1424-30. PubMed ID: 18282597
[TBL] [Abstract][Full Text] [Related]
45. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
46. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma.
Donoghue S; Baden HS; Lauder I; Sobolewski S; Pringle JH
Cancer Res; 1999 Oct; 59(20):5386-91. PubMed ID: 10537324
[TBL] [Abstract][Full Text] [Related]
48. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.
Chang CC; Liu YC; Cleveland RP; Perkins SL
Am J Clin Pathol; 2000 Apr; 113(4):512-8. PubMed ID: 10761452
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of GST-pi expression in diffuse large B-cell lymphomas.
Ribrag V; Koscielny S; Carpiuc I; Cebotaru C; Vande Walle H; Talbot M; Fenaux P; Bosq J
Leukemia; 2003 May; 17(5):972-7. PubMed ID: 12750712
[TBL] [Abstract][Full Text] [Related]
50. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
[TBL] [Abstract][Full Text] [Related]
51. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
[TBL] [Abstract][Full Text] [Related]
52. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification.
Baars JW; de Jong D; Willemse EM; Gras L; Dalesio O; v Heerde P; Huygens PC; vd Lelie H; Kr vd Borne AE
Br J Cancer; 1999 Apr; 79(11-12):1770-6. PubMed ID: 10206291
[TBL] [Abstract][Full Text] [Related]
53. Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell.
Liang R; Todd D; Ho FC
Hematol Oncol; 1996 Mar; 14(1):1-6. PubMed ID: 8613131
[TBL] [Abstract][Full Text] [Related]
54. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
Lossos IS; Czerwinski DK; Alizadeh AA; Wechser MA; Tibshirani R; Botstein D; Levy R
N Engl J Med; 2004 Apr; 350(18):1828-37. PubMed ID: 15115829
[TBL] [Abstract][Full Text] [Related]
55. [Histological and immunohistochemical characteristics of diffuse large cell B-cell lymphomas].
Krivolapov IuA; Saltykova LB; Kozlova AA
Arkh Patol; 2000; 62(6):19-24. PubMed ID: 11198116
[TBL] [Abstract][Full Text] [Related]
56. Cyclin D3 expression in normal, reactive and neoplastic tissues.
Doglioni C; Chiarelli C; Macrí E; Dei Tos AP; Meggiolaro E; Dalla Palma P; Barbareschi M
J Pathol; 1998 Jun; 185(2):159-66. PubMed ID: 9713342
[TBL] [Abstract][Full Text] [Related]
57. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Filipits M; Jaeger U; Simonitsch I; Chizzali-Bonfadin C; Heinzl H; Pirker R
Clin Cancer Res; 2000 Sep; 6(9):3417-23. PubMed ID: 10999723
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.
Muris JJ; Meijer CJ; Cillessen SA; Vos W; Kummer JA; Bladergroen BA; Bogman MJ; MacKenzie MA; Jiwa NM; Siegenbeek van Heukelom LH; Ossenkoppele GJ; Oudejans JJ
Leukemia; 2004 Mar; 18(3):589-96. PubMed ID: 14712286
[TBL] [Abstract][Full Text] [Related]
59. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
60. Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma.
Aviles A; Yañez J; López T; García EL; Guzmán R; Díaz-Maqueo JC
Arch Med Res; 1995; 26(1):31-4. PubMed ID: 7711444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
